Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.320 -0.040 (-2.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
From Biomea Fusion, Inc.
Via GlobeNewswire
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
Why Shares of Biomea Fusion Jumped This Week
The company launched its second trial this year for its lead therapy. 
Via The Motley Fool
Biomea Fusion To Participate In Upcoming Investor Events
From Biomea Fusion, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
 
Via Benzinga
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
From Biomea Fusion, Inc.
Via GlobeNewswire
Analyst Expectations for Biomea Fusion's Future
 
Via Benzinga
Biomea Fusion: Q2 Earnings Insights
Biomea Fusion (NASDAQ:BMEA) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
US Stocks Edge Lower; Bank of America Profit Tops Views
U.S. stocks traded lower this morning, with the Dow Jones dropping around 50 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
From Biomea Fusion, Inc.
Via GlobeNewswire
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
Via MarketBeat
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
From Biomea Fusion, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
From Biomea Fusion, Inc.
Via GlobeNewswire
BMF-219 Enters the Clinic for KRAS Solid Tumors
From Biomea Fusion, Inc.
Via GlobeNewswire
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate
Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting.  
Via Benzinga
How Is The Market Feeling About Biomea Fusion?
Biomea Fusion's (NASDAQ:BMEA) short percent of float has fallen 17.37% since its last report. The company recently reported that it has 451 thousand shares sold short,... 
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting
Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor. Multiple myeloma (MM) is a... 
Via Benzinga
69 Biggest Movers From Yesterday
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.